כל המחקרים
פעיל אך לא מגייסתצפיתי

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

This study, called a "Natural History Study," aims to gather information about children and young people up to 18 who have a heart condition known as cardiomyopathy. This specific type of cardiomyopathy is linked to a fault in a gene called MYBPC3. Researchers want to understand more about how the condition progresses over time, its effects on daily life, common risk factors, and the overall quality of life for those affected. They are also interested in learning about the different treatments, procedures, and long-term outcomes for these children. The study will collect information from existing medical records and, in some cases, follow children over time.

במבט חטוף

סטטוס
פעיל אך לא מגייס
נותן חסות
Tenaya Therapeutics
יעד הרשמה
200
התחל
01 Nov 2021
השלמה משוערת
01 יוני 2028

על מה המחקר הזה?

This study is called a "natural history study." Think of it like watching how a plant grows from a seed – it's about understanding how a condition develops and changes over time, without trying new treatments. Here, researchers are focusing on a particular heart condition in children and young people (up to 18 years old) called cardiomyopathy.

Cardiomyopathy means the heart muscle is abnormal, which can make it harder for the heart to pump blood effectively. In this study, they are specifically looking at cases where the cardiomyopathy is caused by a change (a 'mutation') in a gene called MYBPC3. Genes are like the instructions in our body, and a change in this gene can affect how the heart muscle works.

The main goal is to collect detailed information from existing medical records of children with this specific genetic change. They want to learn about how the condition affects daily life, what treatments have been used, and how children are doing long-term. This information is really important because it helps doctors and scientists understand the condition better, which can lead to better care and potentially new treatments in the future. They are also looking at whether there are particular things that make the condition worse or better, and how it impacts a child's quality of life.

נקודות עיקריות

  • This study focuses on children and young people (under 18) with a specific heart condition.
  • The heart condition (cardiomyopathy) is linked to a fault in the MYBPC3 gene.
  • It's a 'natural history' study, meaning it observes how the condition develops over time.
  • The study primarily collects information from existing medical records.
  • No new treatments or tests will be given as part of this study.
  • The goal is to improve understanding and future care for children with this condition.

מי עשוי להיות זכאי?

To be considered for this study, children and young people must be under 18 years old. They need to have had a genetic test that confirmed a change in their MYBPC3 gene, which is known to cause heart problems.

For information taken from past medical records, the child must have been under 18 when the information was recorded or when they passed away. There's a special rule for very young babies with two copies of the faulty gene where older records can be included.

For new information being collected (going forward), children also need to be under 18 and have the MYBPC3 gene change. They must also have been diagnosed with cardiomyopathy. If a child is already taking part in another study where a new treatment is being tested, they might not be able to join this one unless specific approval is given. Also, if a child has another serious illness that is expected to significantly shorten their life, they would not be eligible.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Is my child under 18 years old?
  2. Has my child had a genetic test showing a faulty MYBPC3 gene?
  3. Has my child been diagnosed with cardiomyopathy?
  4. Is my child currently not in another clinical trial testing a new treatment?
  5. Does my child not have any other severe illnesses that greatly shorten life expectancy?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

This study primarily involves collecting information from your child's existing medical records. This means researchers will look at past details about their condition, treatments they've received, and how they progressed. For some children, especially very young infants with specific gene changes or those joining the study currently, there might also be a plan to collect new information ongoingly. This would involve following your child's health and treatment over time through their regular medical appointments and records. You would not need to attend extra visits or take any new experimental medication for this study. The total duration of participation for those followed over time would depend on the study plan and your child's medical care, but it focuses on gathering routine medical data.

סיכונים ותועלות פוטנציאליים

There are no direct medical risks to your child from taking part in this study, as it mainly involves looking at existing medical records or collecting routine information. Your child will not be given any new treatments or procedures specifically for the study. The potential benefit is that the information collected will help doctors and researchers understand cardiomyopathy caused by the MYBPC3 gene better. This improved understanding could eventually lead to better care and treatment options for children with this condition in the future. You always have the right to withdraw your child's information from the study at any time without it affecting their medical care.

מיקומים (29)

  • בית החולים לילדים של ארקנסו
    מיקוד מאומת
    ליטל רוק, ארצות הברית
  • בית החולים לילדים לוס אנג'לס
    מיקוד מאומת
    לוס אנג'לס, ארצות הברית
  • University of California Davis Health
    מיקוד מאומת
    סקרמנטו, ארצות הברית
  • בית החולים לילדים רדי - סן דייגו
    מיקוד מאומת
    סן דייגו, ארצות הברית
  • University of Colorado Hospital - Anschutz Medical Campus
    מיקוד מאומת
    אורורה, ארצות הברית
  • Nemours Alfred I. Dupont Hospital for Children
    מיקוד מאומת
    וילמינגטון, ארצות הברית
  • Joe DiMaggio Children's Hospital
    מיקוד מאומת
    Hollywood, United States
  • Children's Mercy Hospital Kansas
    מיקוד מאומת
    קנזס סיטי, ארצות הברית
  • St. Louis Children's Hospital
    מיקוד מאומת
    סנט לואיס, ארצות הברית
  • Cohen Children's Medical Center
    מיקוד מאומת
    Lake Success, United States
  • הר סיני
    מיקוד מאומת
    ניו יורק, ארצות הברית
  • Columbia University Irving Medical Center
    מיקוד מאומת
    ניו יורק, ארצות הברית

שאלות נפוצות

What is cardiomyopathy?

Cardiomyopathy is a heart condition where the heart muscle is abnormal, which can make it harder for the heart to pump blood effectively around the body.

What does 'MYBPC3 mutation' mean?

It means there's a change or fault in a specific gene called MYBPC3. This gene gives instructions for making a protein important for heart muscle function, and a fault can cause heart problems.

Will my child receive new treatment in this study?

No, this study is about collecting information on how the condition develops and existing treatments. Your child will not receive any new or experimental treatments as part of this study.

מי יכול להשתתף במחקר זה?

Children and young people under 18 who have cardiomyopathy caused by a specific MYBPC3 gene fault are generally eligible. Eligibility depends on whether old records are being reviewed or new information is being collected.

What happens with the information collected?

The information helps doctors and researchers learn more about how this specific heart condition affects children, what treatments work best, and how it impacts their quality of life. This knowledge can lead to better care for children in the future.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.